Literature DB >> 5118468

Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms.

G Medoff, M Comfort, G S Kobayashi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5118468     DOI: 10.3181/00379727-138-35943

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


× No keyword cloud information.
  51 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

2.  In vitro studies with combinations of 5-fluorocytosine and amphotericin B.

Authors:  S Shadomy; G Wagner; E Espinel-Ingroff; B A Davis
Journal:  Antimicrob Agents Chemother       Date:  1975-08       Impact factor: 5.191

Review 3.  Principles of combination therapy.

Authors:  S Levin; A A Harris
Journal:  Bull N Y Acad Med       Date:  1975-10

Review 4.  New antifungal therapy in ophthalmology.

Authors:  T W Lieberman; I H Leopold
Journal:  Trans Am Ophthalmol Soc       Date:  1973

Review 5.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

Review 6.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

7.  Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.

Authors:  Patrick Schwarz; Guilhem Janbon; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

8.  Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

9.  Cryptococcal meningitis.

Authors:  T L Tjia; Y K Yeow; C B Tan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-09       Impact factor: 10.154

10.  Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine.

Authors:  J Arroyo; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.